Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): A randomised, double-blind, phase II trial

Mega, J. L., Braunwald, E., Mohanavelu, S., Burton, P., Poulter, R., Misselwitz, F., Hricak, V., Barnathan, E. S., Bordes, P., Witkowski, A., Markov, V., Oppenheimer, L. and Gibson, C. M. (2009) Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): A randomised, double-blind, phase II trial. Lancet, 374 9683: 29-38. doi:10.1016/S0140-6736(09)60738-8

Author Mega, J. L.
Braunwald, E.
Mohanavelu, S.
Burton, P.
Poulter, R.
Misselwitz, F.
Hricak, V.
Barnathan, E. S.
Bordes, P.
Witkowski, A.
Markov, V.
Oppenheimer, L.
Gibson, C. M.
Title Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): A randomised, double-blind, phase II trial
Journal name Lancet   Check publisher's open access policy
ISSN 0140-6736
Publication date 2009-07-01
Sub-type Article (original research)
DOI 10.1016/S0140-6736(09)60738-8
Open Access Status DOI
Volume 374
Issue 9683
Start page 29
End page 38
Total pages 10
Place of publication London, United Kingdom
Publisher The Lancet Publishing Group
Language eng
Formatted abstract
Background Rivaroxaban is an oral direct factor Xa inhibitor that has been effective in prevention of venous thromboembolism in patients undergoing elective orthopaedic surgery. However, its use after acute coronary syndromes has not been investigated. In this setting, we assessed the safety and efficacy of rivaroxaban and aimed to select the most favourable dose and dosing regimen.

Methods In this double-blind, dose-escalation, phase II study, undertaken at 297 sites in 27 countries, 3491 patients stabilised after an acute coronary syndrome were stratified on the basis of investigator decision to use aspirin only (stratum 1, n=761) or aspirin plus a thienopyridine (stratum 2, n=2730). Participants were randomised within each strata and dose tier with a block randomisation method at 1:1:1 to receive either placebo or rivaroxaban (at doses 5–20 mg) given once daily or the same total daily dose given twice daily. The primary safety endpoint was clinically significant bleeding (TIMI major, TIMI minor, or requiring medical attention); the primary efficacy endpoint was death, myocardial infarction, stroke, or severe recurrent ischaemia requiring revascularisation during 6 months. Safety analyses included all participants who received at least one dose of study drug; efficacy analyses were by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00402597.

Three patients in stratum 1 and 26 in stratum 2 never received the study drug. The risk of clinically significant bleeding with rivaroxaban versus placebo increased in a dose-dependent manner (hazard ratios [HRs] 2·21 [95% CI 1·25–3·91] for 5 mg, 3·35 [2·31–4·87] for 10 mg, 3·60 [2·32–5·58] for 15 mg, and 5·06 [3·45–7·42] for 20 mg doses; p<0·0001). Rates of the primary efficacy endpoint were 5·6% (126/2331) for rivaroxaban versus 7·0% (79/1160) for placebo (HR 0·79 [0·60–1·05], p=0·10). Rivaroxaban reduced the main secondary efficacy endpoint of death, myocardial infarction, or stroke compared with placebo (87/2331 [3·9%] vs 62/1160 [5·5%]; HR 0·69, [95% CI 0·50–0·96], p=0·0270). The most common adverse event in both groups was chest pain (248/2309 [10·7%] vs 118/1153 [10·2%]).

Interpretation The use of an oral factor Xa inhibitor in patients stabilised after an acute coronary syndrome increases bleeding in a dose-dependent manner and might reduce major ischaemic outcomes. On the basis of these observations, a phase III study of low-dose rivaroxaban as adjunctive therapy in these patients is underway.

Funding Johnson & Johnson Pharmaceutical Research & Development and Bayer Healthcare AG.
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: ERA 2012 Admin Only
School of Medicine Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 395 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 457 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Thu, 03 Sep 2009, 17:52:54 EST by Mr Andrew Martlew on behalf of Medicine - Princess Alexandra Hospital